Glaxo to Pay $20 Million SEC Fine Over Bribery in ChinaBy
China fined pharmaceutical company $489 million for bribery
SEC says Glaxo had similar improper conduct in other countries
GlaxoSmithKline PLC agreed to pay $20 million to the U.S. Securities and Exchange Commission to settle allegations that a Chinese subsidiary of the pharmaceutical company bribed foreign officials to increase product sales.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.